scholarly journals Comparison of respiratory pathogen colonization and antimicrobial susceptibility in people with cystic fibrosis versus non cystic fibrosis bronchiectasis: A systematic review

2020 ◽  
Author(s):  
Salony Verma ◽  
Joseph L Mathew ◽  
Pallab Ray
Keyword(s):  
Systematic Review ◽  
Cystic Fibrosis ◽  
Respiratory Tract ◽  
Antimicrobial Susceptibility ◽  
Antibiotic Susceptibility ◽  
Bacterial Colonization ◽  
Antimicrobial Treatment ◽  
Respiratory Pathogen ◽  
Forest Plot ◽  
Susceptibility Pattern

Abstract Background Both cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis are characterized by permanent bronchial dilation, leading to impaired mucociliary clearance and development of chronic infections. Although the core airway microbiota in both CF and non-CF bronchiectasis may be similar, particular satellite microbes are associated with specific conditions. Moreover, there are several factors, which may be responsible for the disparity in antibiotic susceptibility profile between the CF and non-CF populations. Hence comparing the microbiota and antibiotic susceptibility pattern in CF bronchiectasis with non-CF bronchiectasis would aid in improved management of both the conditions. Methods Two authors will independently search the electronic databases PubMed and EMBASE for studies reporting bacterial colonization of the respiratory tract determined by examination of any respiratory tract specimen, by conventional bacterial culture or specialized techniques; and/or antimicrobial susceptibility testing in adults and children diagnosed with bronchiectasis in either CF subjects or non-CF subjects. The authors will independently assess the risk of bias for each included study using the Newcastle Ottawa Scale (NOS). We will present the data with descriptive statistics and provide pooled estimates of outcome parameters, wherever it is feasible to perform meta-analysis using a random effects model. Heterogeneity in studies will be explored by visual inspection of forest plot as well as using the Higgins and Thompson I2 method. We will contact the corresponding authors of studies where data is/are missing and try to obtain the missing data. Discussion To date, there are no locally applicable evidence-based guidelines for antimicrobial treatment of non-CF bronchiectasis patients. In general, treatment in non-CF bronchiectasis is based on extrapolation of clinical trials done in subjects with CF bronchiectasis. An insight into the microbiota and antimicrobial susceptibility patterns against specific organisms in both the conditions would facilitate appropriate rather than empiric therapy, and hopefully reduce the burden of antimicrobial resistance created by rampant usage of antibiotics. Therefore, this systematic review is being undertaken to compare the respiratory tract colonization and antibacterial susceptibility pattern in people with cystic fibrosis versus non-cystic fibrosis bronchiectasis. Systematic review registration: The protocol was submitted for publication in PROSPERO on June 26, 2020 (PROSPERO ID: 193859).

scholarly journals Comparison of respiratory pathogen colonization and antimicrobial susceptibility in people with cystic fibrosis bronchiectasis versus non-cystic fibrosis bronchiectasis: a protocol for a systematic review

2021 ◽  
Vol 10 (1) ◽  
Author(s):  
Salony Verma ◽  
Joseph L. Mathew ◽  
Pallab Ray
Keyword(s):  
Systematic Review ◽  
Cystic Fibrosis ◽  
Respiratory Tract ◽  
Antimicrobial Susceptibility ◽  
Antibiotic Susceptibility ◽  
Bacterial Colonization ◽  
Respiratory Pathogen ◽  
Cochrane Library ◽  
The Impact ◽  
Susceptibility Patterns

Abstract Background Both cystic fibrosis (CF) and non-cystic fibrosis bronchiectasis are characterized by permanent bronchial dilation, impaired mucociliary clearance, and development of chronic colonization and infection. Although the major airway microbiota in both CF and non-CF bronchiectasis may be similar, there are some differences in clinical and microbiologic features. There may also be differences in antibiotic susceptibility patterns between the CF and non-CF populations. Therefore, analysis and comparison of the microbiota and antibiotic susceptibility pattern in CF bronchiectasis versus non-CF bronchiectasis would help to improve the management of both conditions. Methods Two authors will independently search the electronic databases PubMed, EMBASE, the Cochrane Library, and LIVIVO, for studies reporting bacterial colonization of the respiratory tract in adults and children diagnosed with bronchiectasis in either CF or non-CF. We will include studies examining any respiratory tract specimen, using conventional bacterial culture or other specialized techniques such as molecular methods. We will also examine the antimicrobial susceptibility patterns in people with CF bronchiectasis versus non-CF bronchiectasis. The authors will independently assess the risk of bias in each included study using the Newcastle Ottawa Scale (NOS). We will present the data with descriptive statistics and provide pooled estimates of outcomes, wherever it is feasible to perform meta-analysis. Heterogeneity in studies will be explored by visual inspection of forest plots as well as using the Higgins and Thompson I2 method. We will contact the corresponding authors of studies where data is/are missing and try to obtain the missing data. We will undertake sensitivity analysis to explore the impact of study quality and subgroup analysis based on pre-set criteria. We will prepare a summary of findings’ table and assess the confidence in the evidence using the GRADE methodology. Discussion To date, there are no locally applicable evidence-based guidelines for antimicrobial treatment of non-CF bronchiectasis patients. In general, treatment is based on extrapolation of evidence in people with CF bronchiectasis. An insight into the microbiota and antimicrobial susceptibility patterns in the two conditions would facilitate appropriate rather than empiric antimicrobial therapy and hopefully reduce the burden of antimicrobial resistance created by rampant usage of antibiotics. Systematic review registration The protocol has been registered in PROSPERO on July 26, 2020 (PROSPERO registration number: CRD42020193859).

Antibiotic susceptibility of bacterial isolates from 502 dogs with respiratory signs

2014 ◽  
Vol 176 (14) ◽  
pp. 357-357 ◽  
Author(s):  
M. Rheinwald ◽  
K. Hartmann ◽  
M. Hähner ◽  
G. Wolf ◽  
R. K. Straubinger ◽  
...  
Keyword(s):  
Antibiotic Susceptibility ◽  
Bacterial Species ◽  
Lavage Fluid ◽  
Respiratory Pathogen ◽  
Susceptibility Pattern ◽  
Gram Positive Bacteria ◽  
Amoxicillin Clavulanic Acid ◽  
Tract Infections ◽  
Cultured Bacteria ◽  
Privately Owned

The aim of this study was to investigate the prevalence of bacterial species isolated from bronchoalveolar lavage fluid (BALF) samples taken from dogs with respiratory signs and to determine their antibiotic susceptibility. Clinical cases were included in the study if they showed signs of respiratory disease and data relating to bacterial culture and susceptibility of BALF samples were available. The medical records of 493 privately owned dogs that were presented between January 1989 and December 2011 were evaluated retrospectively. In 35 per cent of samples, no bacteria were cultured. Bacteria isolated from culture-positive samples included Streptococcus species (31 per cent of positive cultures), Enterobacteriaceae (30 per cent, including Escherichia coli (15 per cent)), Staphylococcus species (19 per cent), Pasteurella species (16 per cent) and Pseudomonas species (14 per cent). Bordetella bronchiseptica as a primary respiratory pathogen was isolated in 8 per cent of cases. Enrofloxacin showed the best susceptibility pattern; 86 per cent of all isolates and 87 per cent of Gram-negative bacteria were susceptible to this antibiotic. Amoxicillin/clavulanic acid yielded the best susceptibility pattern in Gram-positive bacteria (92 per cent). Therefore, these antibiotics can be recommended for empirical or first-line treatment in dogs with bacterial lower respiratory tract infections.

Antibiotic Susceptibility Patterns of Yersinia enterocolitica

1981 ◽  
Vol 44 (2) ◽  
pp. 124-127 ◽  
Author(s):  
L. RESTAINO ◽  
W. M. HILL
Keyword(s):  
Yersinia Enterocolitica ◽  
Antimicrobial Susceptibility ◽  
Antibiotic Susceptibility ◽  
Penicillin G ◽  
Susceptibility Pattern ◽  
Antimicrobial Susceptibility Pattern ◽  
Resistance To Penicillin ◽  
Antibiotic Susceptibility Patterns ◽  
Susceptibility Patterns

Antibiotic susceptibility patterns for Yersinia enterocolitica strains involving 10 different serotypes were analyzed and compared. All Y. enterocolitica were susceptible to colistin, gentamicin, kanamycin, neomycin and doxycycline, whereas all isolates displayed resistance to penicillin G, methicillin (derivative of penicillin), novobiocin, and clindamycin. The antibiograms for the Y. enterocolitica isolates were in some instances related to the somatic serotypes, especially serotype 0:8 for which the antimicrobial susceptibility pattern displayed the greatest disparity. By eliminating the antibiograms for the four serotype 0:8 strains, antimicrobial susceptibility patterns for atypical and typical strains were similar.

scholarly journals Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections

2019 ◽  
Vol 69 (10) ◽  
pp. 1812-1816 ◽  
Author(s):  
Valerie J Waters ◽  
Timothy J Kidd ◽  
Rafael Canton ◽  
Miquel B Ekkelenkamp ◽  
Helle Krogh Johansen ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Clinical Response ◽  
Antimicrobial Susceptibility ◽  
Susceptibility Testing ◽  
Treatment Effectiveness ◽  
Research Priorities ◽  
Genotypic Diversity ◽  
Antimicrobial Treatment ◽  
Antimicrobial Susceptibility Testing ◽  
Lung Infections

AbstractMedian cystic fibrosis (CF) survival has increased dramatically over time due to several factors, including greater availability and use of antimicrobial therapies. During the progression of CF lung disease, however, the emergence of multidrug antimicrobial resistance can limit treatment effectiveness, threatening patient longevity. Current planktonic-based antimicrobial susceptibility testing lacks the ability to predict clinical response to antimicrobial treatment of chronic CF lung infections. There are numerous reasons for these limitations including bacterial phenotypic and genotypic diversity, polymicrobial interactions, and impaired antibiotic efficacy within the CF lung environment. The parallels to other chronic diseases such as non-CF bronchiectasis are discussed as well as research priorities for moving forward.

Sign in / Sign up

Export Citation Format

Share Document